IP Library Granted Patent US 12,611,451
Granted Patent B2
US 12,611,451 · App. 18/330,560 · Granted Apr 28, 2026

Neisseria meningitidis vaccine

Inventors: Richard David Kensinger, Jr. (Henryville, PA); Steven L. Hauser (Easton, PA)
Assignee: SANOFI VACCINES US INC.
A61K39/095A61K47/18A61K47/36A61K47/6415A61K47/65A61K2039/55583A61K2039/6037A61K2039/70Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,611,451
App. No.
18/330,560
Granted
Apr 28, 2026
Kind
B2
Abstract

Provided herein are compounds, compositions, formulations, kits, uses, and methods for vaccinating a subject against Neisseria meningitidis.

Claims (27)

1 . A method of producing a conjugate of a Neisseria meningitidis capsular polysaccharide to a carrier protein, comprising:

a) partially de-O-acetylating the polysaccharide by alkaline hydrolysis to an O-acetylation level ranging from 0.6 μmol/mg polysaccharide to 1.5 μmol/mg polysaccharide;

b) activating the polysaccharide by periodate treatment, thereby converting diols to aldehydes to an extent of at least 20 nmol aldehyde per mg polysaccharide; and

c) conjugating the activated polysaccharide to the carrier protein by reductive amination, wherein the polysaccharide is present in the conjugation reaction at a weight-to-weight ratio of 1:1 to 5:1 relative to the carrier protein, thereby forming the conjugate;

wherein the conjugate is a population comprising double-end-linked conjugated polysaccharides and single-end-linked conjugated polysaccharides which are both directly attached to the carrier protein through a secondary amine,

wherein the polysaccharides of the conjugate to the carrier protein have an O-acetylation level ranging from 0.6 μmol/mg polysaccharide to 1.5 μmol/mg polysaccharide,

wherein the polysaccharide is MenC capsular polysaccharide, and

wherein the carrier protein is tetanus toxoid.

2 . The method of claim 1 , wherein the polysaccharide is present in the conjugation reaction at a weight-to-weight ratio of 1.5:1 to 3:1 relative to the carrier protein.

3 . The method of claim 1 , wherein the de-O-acetylation reduces the initial amount of O-acetylation in the polysaccharide by 40% to 70%.

4 . The method of claim 1 , wherein the activated polysaccharide is at a starting concentration of 20 g/L to 50 g/L in the conjugation reaction.

5 . The method of claim 1 , wherein the polysaccharide is reduced in size to 30 kDa to 150 kDa.

6 . The method of claim 5 , wherein the polysaccharide is reduced in size by acid hydrolysis and/or heat.

7 . The method of claim 5 , wherein the polysaccharide is reduced in size by oxidative cleavage.

8 . The method of claim 1 , further comprising purifying the conjugate by hydrophobic interaction chromatography.

9 . The method of claim 1 , further comprising purifying the conjugate by mixed mode resin chromatography.

10 . The method of claim 1 , wherein the conjugate has a weight average molecular weight ranging from 300 kDa to 1500 kDa.

11 . The method of claim 1 , wherein the conjugate is a population comprising molecules having a molecular weight in the range of 700 kDa to 1400 kDa.

12 . The method of claim 1 , wherein the conjugate is a population comprising molecules having a molecular weight in the range of 800 kDa to 1300 kDa.

13 . The method of claim 1 , wherein the conjugate comprises one or more modifications selected from (i) a primary hydroxyl at the 7 position, (ii) a (2-hydroxy) ethoxy at the reducing end, and (iii) a secondary amine conjugated to the carrier protein, wherein the modifications are present at no less than 25 nmol/mg polysaccharide.

14 . The method of claim 1 , wherein the conjugate has a MenC capsular polysaccharide to carrier protein mass ratio of 0.3 to 1.1.

15 . The method of claim 1 , wherein the conjugate has a MenC capsular polysaccharide to carrier protein mass ratio of 0.4 to 0.8.

16 . The method of claim 1 , wherein the O-acetylation level of the polysaccharide ranges from 0.8 μmol/mg polysaccharide to 1.4 μmol/mg polysaccharide.

17 . The method of claim 5 , wherein the molecular weight is determined by multi-angle light scattering (MALS).

18 . The method of claim 1 , wherein reductive amination comprises reducing imines to amines using a cyanoborohydride, pyridine borane (C 5 H 8 BN), or picoline borane complex (C 6 H 7 N·BH 3 ).

19 . The method of claim 1 , further comprising converting unreacted aldehydes in the conjugate to alcohols with a reducing reagent, wherein the reducing reagent is a borohydride.

20 . The method of claim 1 , wherein periodate is added to a concentration of 1 mM to 4 mM to activate the polysaccharide.

Assignments (2)
CHANGE OF NAME Recorded Jan 26, 2026
From: SANOFI PASTEUR INC.
To: SANOFI VACCINES US INC.
Reel/Frame 074482/0847 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2023
From: KENSINGER, RICHARD DAVID, JR.; HAUSER, STEVEN L.
To: SANOFI PASTEUR INC.
Reel/Frame 064242/0967 →
Continuity (7)
Division 17468989 · Sep 8, 2021
Division 16282080 · Feb 21, 2019
Continuation PCTUS2017049856 · Sep 1, 2017
Provisional Application 62505525 · May 12, 2017
Provisional Application 62468695 · Mar 8, 2017
Provisional Application 62383279 · Sep 2, 2016
Related Publication 20230310567A1 · Oct 5, 2023
References Cited (302)
US 4673574A · Anderson · 1987 [cited by applicant]
US 4695624A · Marburg et al. · 1987 [cited by applicant]
US 4882317A · Marburg et al. · 1989 [cited by applicant]
US 5097020A · Anderson et al. · 1992 [cited by applicant]
US 5371197A · Marburg et al. · 1994 [cited by applicant]
US 5425946A · Tai et al. · 1995 [cited by applicant]
US 6146902A · McMaster · 2000 [cited by applicant]
US 6309633B1 · Ekwuribe et al. · 2001 [cited by applicant]
US 6309646B1 · Lees · 2001 [cited by applicant]
US 6645503B1 · Arumugham et al. · 2003 [cited by applicant]
US 6656472B1 · Chong et al. · 2003 [cited by applicant]
US 6673905B2 · Pozsgay · 2004 [cited by applicant]
US 6933137B2 · Egen et al. · 2005 [cited by applicant]
US 7018637B2 · Chong et al. · 2006 [cited by applicant]
US 7491517B2 · Reddy · 2009 [cited by applicant]
US 7588765B2 · Porro · 2009 [cited by applicant]
US 7927858B2 · Mayeresse · 2011 [cited by applicant]
US 7935787B2 · Khandke et al. · 2011 [cited by applicant]
US 7972608B2 · Kim et al. · 2011 [cited by applicant]
US 8007807B2 · Borkowski · 2011 [cited by applicant]
US 8048432B2 · Lee et al. · 2011 [cited by applicant]
US 8062641B2 · Oscarson et al. · 2011 [cited by applicant]
US 8129147B2 · Reddy · 2012 [cited by applicant]
US 8163296B2 · Capannoli et al. · 2012 [cited by applicant]
US 8329184B2 · Biemans et al. · 2012 [cited by applicant]
US 8361477B2 · Borkowski · 2013 [cited by applicant]
US 8398983B2 · Biemans et al. · 2013 [cited by applicant]
US 8398985B2 · Kapre et al. · 2013 [cited by applicant]
US 8431136B2 · Biemans et al. · 2013 [cited by applicant]
US 8444992B2 · Borkowski · 2013 [cited by applicant]
US 8449865B2 · Mayeresse · 2013 [cited by applicant]
US 8465749B2 · Lee et al. · 2013 [cited by applicant]
US 8492364B2 · Pier et al. · 2013 [cited by applicant]
US 8529908B2 · Marshall · 2013 [cited by applicant]
US 8551527B2 · Chouvenc et al. · 2013 [cited by applicant]
US 8562999B2 · Khandke et al. · 2013 [cited by applicant]
US 8598337B2 · Michon et al. · 2013 [cited by applicant]
US 8642042B2 · Mekalanos · 2014 [cited by applicant]
US 8722062B2 · Ryall · 2014 [cited by applicant]
US 8753645B2 · Biemans et al. · 2014 [cited by applicant]
US 8753649B2 · Lee et al. · 2014 [cited by applicant]
US 8753651B2 · Costantino · 2014 [cited by applicant]
US 8765135B2 · Contorni · 2014 [cited by applicant]
US 8784826B2 · Borkowski · 2014 [cited by applicant]
US 8846049B2 · Biemans et al. · 2014 [cited by applicant]
US 8852606B2 · Costantino · 2014 [cited by applicant]
US 8883163B2 · Biemans et al. · 2014 [cited by applicant]
US 8883166B2 · Contorni et al. · 2014 [cited by applicant]
US 8889152B2 · Costantino · 2014 [cited by applicant]
US 8986710B2 · Anderson et al. · 2015 [cited by applicant]
US 8999354B2 · Ryall · 2015 [cited by applicant]
US 9040058B2 · Blackkolb et al. · 2015 [cited by applicant]
US 9102699B2 · Jain et al. · 2015 [cited by applicant]
US 9120848B2 · Kaplan · 2015 [cited by applicant]
US 9173931B2 · Jessouroun et al. · 2015 [cited by applicant]
US 9173954B2 · Costantino et al. · 2015 [cited by applicant]
US 9173955B2 · Ryall · 2015 [cited by applicant]
US 9175033B2 · Lee · 2015 [cited by applicant]
US 9180204B2 · Contorni · 2015 [cited by applicant]
US 9198976B2 · Lee et al. · 2015 [cited by applicant]
US 9198977B2 · Kapre et al. · 2015 [cited by applicant]
US 9216223B2 · Mekalanos · 2015 [cited by applicant]
US 9283270B2 · Kapre et al. · 2016 [cited by applicant]
US 9333247B2 · Moe et al. · 2016 [cited by applicant]
US 9358278B2 · Costantino · 2016 [cited by applicant]
US 9358279B2 · Biemans et al. · 2016 [cited by applicant]
US 9358302B2 · Avci et al. · 2016 [cited by applicant]
US 9402915B2 · Marshall · 2016 [cited by applicant]
US 9427476B2 · Lee et al. · 2016 [cited by applicant]
US 9452207B2 · Costantino · 2016 [cited by applicant]
US 9452224B2 · Jain et al. · 2016 [cited by applicant]
US 9463250B2 · Bigio et al. · 2016 [cited by applicant]
US 9474795B2 · Lee et al. · 2016 [cited by applicant]
US 9486515B2 · Biemans et al. · 2016 [cited by applicant]
US 9492558B2 · Costantino · 2016 [cited by applicant]
US 9493517B2 · Costantino et al. · 2016 [cited by applicant]
US 9511132B2 · Contorni · 2016 [cited by applicant]
US 9517274B2 · Gu et al. · 2016 [cited by applicant]
US 9533032B2 · Mekalanos · 2017 [cited by applicant]
US 9580734B2 · Shankar et al. · 2017 [cited by applicant]
US 9636393B2 · Giuliani et al. · 2017 [cited by applicant]
US 9724401B2 · Killeen et al. · 2017 [cited by applicant]
US 9782466B2 · Constantino · 2017 [cited by applicant]
US 9782467B2 · Costantino · 2017 [cited by applicant]
US 9782468B2 · Damotharan et al. · 2017 [cited by applicant]
US 9789179B2 · Biemans et al. · 2017 [cited by applicant]
US 9803030B2 · Bardotti et al. · 2017 [cited by applicant]
US 9827301B2 · Costantino et al. · 2017 [cited by applicant]
US 9844601B2 · Ryall · 2017 [cited by applicant]
US 9931397B2 · Biemans et al. · 2018 [cited by applicant]
US 10011662B2 · Gill et al. · 2018 [cited by applicant]
US 10064932B2 · Marshall · 2018 [cited by applicant]
US 11147866B2 · Kensinger, Jr. et al. · 2021 [cited by applicant]
US 20050002957A1 · Ryall · 2005 [cited by applicant]
US 20070020293A1 · Michon · 2007 [cited by applicant]
US 20070116714A1 · Slaoui et al. · 2007 [cited by applicant]
US 20080193476A1 · Biemans et al. · 2008 [cited by applicant]
US 20090041802A1 · Biemans et al. · 2009 [cited by applicant]
US 20090136541A1 · Biemans et al. · 2009 [cited by applicant]
US 20090252759A1 · Biemans et al. · 2009 [cited by applicant]
US 20090311285A1 · Biemans et al. · 2009 [cited by applicant]
US 20100203137A1 · Contorni et al. · 2010 [cited by applicant]
US 20100285069A1 · Contorni et al. · 2010 [cited by applicant]
US 20120207780A1 · Boutriau et al. · 2012 [cited by applicant]
US 20130189295A1 · Arico et al. · 2013 [cited by applicant]
US 20130209503A1 · Kapre et al. · 2013 [cited by applicant]
US 20140112950A1 · Singh et al. · 2014 [cited by applicant]
US 20140234368A1 · Costantino et al. · 2014 [cited by applicant]
US 20150004191A1 · Contorni · 2015 [cited by applicant]
US 20150044253A1 · Biemans et al. · 2015 [cited by applicant]
US 20150093411A1 · Michon et al. · 2015 [cited by applicant]
US 20150104479A1 · Romano et al. · 2015 [cited by applicant]
US 20150165016A1 · Pier et al. · 2015 [cited by applicant]
US 20150190493A1 · Baudner et al. · 2015 [cited by applicant]
US 20160101187A1 · Berti et al. · 2016 [cited by applicant]
US 20160175421A1 · Wong et al. · 2016 [cited by applicant]
US 20160228529A1 · Contorni et al. · 2016 [cited by applicant]
US 20160237116A1 · Usera et al. · 2016 [cited by applicant]
US 20160297895A1 · Saul et al. · 2016 [cited by applicant]
US 20170000874A1 · Jianhua · 2017 [cited by applicant]
US 20170037440A1 · Fiebig et al. · 2017 [cited by applicant]
US 20170066794A1 · Gill et al. · 2017 [cited by applicant]
US 20170080080A1 · Trent et al. · 2017 [cited by applicant]
US 20190175718A1 · Kensinger, Jr. et al. · 2019 [cited by applicant]
US 20210401964A1 · Kensinger, Jr. et al. · 2021 [cited by applicant]
AU 2012203419B2 · 2014 [cited by applicant]
CN 1703241A · 2005 [cited by applicant]
CN 1890261A · 2007 [cited by applicant]
CN 100338218C · 2007 [cited by applicant]
CN 101048177A · 2007 [cited by applicant]
CN 101208102A · 2008 [cited by applicant]
CN 101448518A · 2009 [cited by applicant]
CN 101448522A · 2009 [cited by applicant]
CN 102596240B · 2012 [cited by applicant]
CN 101863998B · 2012 [cited by applicant]
CN 102809656B · 2012 [cited by applicant]
CN 102917730A · 2013 [cited by applicant]
CN 101374548B · 2013 [cited by applicant]
CN 102755631B · 2015 [cited by applicant]
CN 104225587B · 2017 [cited by applicant]
EP 0562107B1 · 1993 [cited by applicant]
EP 0658118B1 · 1995 [cited by examiner]
EP 0941738B1 · 1999 [cited by applicant]
EP 1109576B1 · 2001 [cited by applicant]
EP 1163008B1 · 2003 [cited by applicant]
EP 1124576B1 · 2004 [cited by applicant]
EP 1587537B1 · 2005 [cited by applicant]
EP 1651261B1 · 2006 [cited by applicant]
EP 1678212B1 · 2006 [cited by applicant]
EP 1140156B1 · 2006 [cited by applicant]
EP 1762245B1 · 2007 [cited by applicant]
EP 1778291B1 · 2007 [cited by applicant]
EP 1501542B2 · 2007 [cited by applicant]
EP 1896065B1 · 2008 [cited by applicant]
EP 1638601B1 · 2008 [cited by applicant]
EP 2004225B1 · 2008 [cited by applicant]
EP 2032160B2 · 2009 [cited by applicant]
EP 2056871B1 · 2009 [cited by applicant]
EP 1755662B1 · 2009 [cited by applicant]
EP 1409013B1 · 2009 [cited by applicant]
EP 1835939B1 · 2010 [cited by applicant]
EP 1741442B1 · 2010 [cited by applicant]
EP 2208999B1 · 2010 [cited by applicant]
EP 2229954B1 · 2010 [cited by applicant]
EP 2277536B1 · 2011 [cited by applicant]
EP 2170391B1 · 2011 [cited by applicant]
EP 2374473B1 · 2011 [cited by applicant]
EP 2376112B1 · 2011 [cited by applicant]
EP 2366404B1 · 2012 [cited by applicant]
EP 2263688B1 · 2012 [cited by applicant]
EP 1265633B1 · 2012 [cited by applicant]
EP 2172213B1 · 2013 [cited by applicant]
EP 2683408B1 · 2014 [cited by applicant]
EP 2180901B1 · 2014 [cited by applicant]
EP 2815762B1 · 2014 [cited by applicant]
EP 1885734B1 · 2015 [cited by applicant]
EP 1993604B1 · 2015 [cited by applicant]
EP 2950815B1 · 2015 [cited by applicant]
EP 2976101A1 · 2016 [cited by applicant]
EP 2184071B1 · 2016 [cited by applicant]
EP 1777236B1 · 2016 [cited by applicant]
EP 2351578B1 · 2017 [cited by applicant]
EP 2118145B1 · 2017 [cited by applicant]
EP 3006041B1 · 2017 [cited by applicant]
EP 2216044B1 · 2018 [cited by applicant]
EP 2878307B1 · 2019 [cited by applicant]
ES 2367918T3 · 2011 [cited by applicant]
IN 101708333B · 2014 [cited by applicant]
JP 2015134829A · 2015 [cited by applicant]
WO 9629094A1 · 1996 [cited by applicant]
WO 1999018121A1 · 1999 [cited by applicant]
WO 2000038711A2 · 2000 [cited by applicant]
WO 2002058737A1 · 2002 [cited by applicant]
WO 2002058737A2 · 2002 [cited by applicant]
WO 2004033623A2 · 2004 [cited by applicant]
WO 2004103400A2 · 2004 [cited by applicant]
WO 2006034320A2 · 2006 [cited by applicant]
WO 2007000314A2 · 2007 [cited by applicant]
WO 2007000322A1 · 2007 [cited by applicant]
WO 2007000327A1 · 2007 [cited by applicant]
WO 2007000341A2 · 2007 [cited by applicant]
WO 2007000343A2 · 2007 [cited by applicant]
WO 2007102797A2 · 2007 [cited by applicant]
WO 2007000342A2 · 2008 [cited by applicant]
WO 2008081014A2 · 2008 [cited by applicant]
WO 2009150543A2 · 2009 [cited by applicant]
WO 2011110531A2 · 2011 [cited by applicant]
WO 2012119972A1 · 2012 [cited by applicant]
WO 2013114268A1 · 2013 [cited by applicant]
WO 2014009971A2 · 2014 [cited by applicant]
WO 2014097099A2 · 2014 [cited by applicant]
WO 2014147044A1 · 2014 [cited by applicant]
WO 2014188313A1 · 2014 [cited by applicant]
WO 2015052684A1 · 2015 [cited by applicant]
WO 2015084846A1 · 2015 [cited by applicant]
WO 2015052684A2 · 2015 [cited by applicant]
WO 2015121783A1 · 2015 [cited by applicant]
WO 2015181834A2 · 2016 [cited by applicant]
WO 2016055957A1 · 2016 [cited by applicant]
WO 2016132294A1 · 2016 [cited by applicant]
WO 2015175355A1 · 2016 [cited by applicant]
WO 2016174683A1 · 2016 [cited by applicant]
WO 2017006349A1 · 2017 [cited by applicant]
WO 2017036138A1 · 2017 [cited by applicant]
WO 2017085602A1 · 2017 [cited by applicant]
WO 2017158480A1 · 2017 [cited by applicant]
WO 2018045286A1 · 2018 [cited by applicant]
WO 2018156467A1 · 2018 [cited by applicant]
Gudlavalleti et al. 2007 (Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylate… [cited by examiner]
Ravenscroft et al. 2015 (Glycoconjugate Vaccines. In: Nunnally, B., Turula, V., Sitrin, R. (eds) Vaccine Analysis: Strategies, Principles, and Control. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-450… [cited by examiner]
Berti et al. 2018 (Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines; Molecules 23: 1340) (Year: 2018). [cited by examiner]
Michon et al. 2000 (Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: Effect of O-acetylation on the nature of the protective epitope. Dev. Biol. (Basel) 2000, 103, 151-160) … [cited by examiner]
Vodopija et al. 1983 (Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide. Infect. Immun. 1983, 42, 59… [cited by examiner]
Peltola et al. 1985 (Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysacchar… [cited by examiner]
Pichichero et al. 1985 (Immunogenicity of O-acetyl-negative and -positive polysaccharide vaccines for infections with Neisseria meningitidis group C in infants. J. Infect. Dis. 1985, 152, 850-851); (Year: 1985). [cited by examiner]
Borrow, R. et al. 2009 (Prevention of meningococcal serogroup C disease by NeisVac-C. Expert. Rev. Vaccines 2009, 8, 265-279). (Year: 2009). [cited by examiner]
Lee et al. 2009 (Preparation and characterization of an immunogenic meningococcal Group A conjugate vaccine for use in Africa. Vaccine 27(5):726-732) (Year: 2009). [cited by examiner]
WHO 2004 (Recommendations for the production and control of meningococcal group C conjugate vaccines; WHO technical report, series 924, annex 2, pp. 102-128) (Year: 2004). [cited by examiner]
Kao et al. 2004 (Quantification of O-acetyl, N-acetyl and phosphate groups and determination of the extent of O-acetylation in bacterial vaccine polysaccharides by high-performance aninon-exchange chromatography with co… [cited by examiner]
Michon et al. 2000 (Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: Effect of O-acetylation on the nature of the protective epitope. Dev. Biol. (Basel) 103, 151-160). (Year… [cited by examiner]
Ravenscroft et al. 2015 (Glycoconjugate Vaccines; In: Nunnally, Turula & Sitrin; Vaccine Analysis: Strategies, Principles, and Control. Springer, Berlin, Heidelberg) (Year: 2015). [cited by examiner]
Anderson, G.W., “N, N'-Carbonyldiimidazole, a new reagent for peptide synthesis”, J. Am. Chem. Soc., 80, 4323 (1958). [cited by applicant]
Assaf-Casals et al: “Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence”; Human Vaccines and Immunoth… [cited by applicant]
Baltzly et al, “The Aminolysis of Esters. A Preliminary Study”, J. Am. Chem. Soc. 1950, v72, pp. 4149-4152. [cited by applicant]
Bartling et al., “Synthesis of a matrix-supported enzyme in non-aqueous conditions”, Nature (London) 243, pp. 342-344 (1973). [cited by applicant]
Baxter et al., “Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults”, The Pediatric Infectious Disease Jou… [cited by applicant]
Baxter et al., “Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 years of Age”, The Pediatric Infectious D… [cited by applicant]
Beresford et al., “Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM197, Dt and TT glycoconjugate vaccines”, Vaccine (2017), http://dx.doi.org/10.1016/j.vaccine.2017.03.066. [cited by applicant]
Bermal et al., “Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults”, Human Vaccines, 7:2, pp. 239-247 (2011). [cited by applicant]
Berti et al., “Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines”, Molecules, 2018, 23, 1340. [cited by applicant]
Bessi et al., “Science vs Conspiracy: Collective Narratives in the Age of Misinformation”, Plos One, 10(2):e0118093 (Feb. 23, 2015). [cited by applicant]
Bethell, et al. “A novel method of activation of cross-linked agaroses with 1,1′-carbonyldiimidazole which gives a matrix for affinity chromatography devoid of additional charged groups”, J. Biol. Chem., 254, pp. 2572-2… [cited by applicant]
Borja-Tabora et al., “Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of a… [cited by applicant]
Borjo-Tabora et al., “Research Article Open Access Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in a… [cited by applicant]
Broker et al., “Factors contributing to the immunogenicity of meningococcal conjugate vaccines”, Human Vaccines & Immunotherapeutics, 12(7), pp. 1808-1824 (2016). [cited by applicant]
Cornish et al., “Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered to infants and toddlers”, 20th International Pathogenic Neisseria Conference, Manch… [cited by applicant]
Cornish et al., “Safety and Immunogenicity of an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered to Infants and Toddlers”, 20th International Pathogenic Neisseria Conference, Manch… [cited by applicant]
Dbaibo et al. “Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACQY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Labe… [cited by applicant]
Dbaibo et al., “The immunogenicity and safetyof an investigational meningococcal serogroups A,C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide v… [cited by applicant]
Dhillon et al: “Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACCWY-TT; Nimenrix) : A review”; Drugs; vol. 77, No. 17, 2017, pp. 1881-1896. [cited by applicant]
Findlow et al., “the Global Meningococcal Initiative: Current Strategies for the Prevention of Meningococcal Disease and the Importance of Herd Protection”, Global Meningococcal Initiative, International Pathogenic Neis… [cited by applicant]
Frasch, “Preparation of bacterial polysaccharide-protein conjugates: Analytical and manufacturing challenges”, Vaccine, vol. 27, Issue 46, Oct. 30, 2009, pp. 6468-6470. [cited by applicant]
Ghanem et al., “Quadrivalent meningococcal serogroups A,C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review”, Expert Opinion on Biological Therapy, 13(8), pp. 1197-1205 (Jul. 2, 2013). [cited by applicant]
Halperin et al., “Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccin… [cited by applicant]
Hearn et al., “Application of 1,1′-carbonyldiimidazole-activated agarose for the purification of proteins”, J. Chromatogr, 185, pp. 463-470 (1979). [cited by applicant]
Hearn et al., “Preparative and analytical applications of CDI-mediated affinity chromatography”, Affinity Chromatography and Biological Recognition, pp. 191-196. Academic Press, New York (1983). [cited by applicant]
Hedari et al., “Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease”, Infection and Drug Resistance, 7, pp. 85-99 (2014). [cited by applicant]
Hermanson et al., “3. N, N'-Carbonyldiimidazole”, Bioconjugate Techniques, pp. 183-185 (1996). [cited by applicant]
Hermanson, G.T., “1.4 CDA Activation and Coupling”, Bioconjugate Techniques, pp. 615-617 (1996). [cited by applicant]
Hinman et al., “The Reactions of Methylhydrazine and unsym-Dimethylhydrazine with Esters and Anhydrides of Carboxylic Acids; the Application of Paper Chromatography to Problems in Synthetic Organic Chemistry,”, J. Am. C… [cited by applicant]
International Search Report and Written Opinion received in connection with international application No. PCT/US2017/049856; mailed Dec. 21, 2017. [cited by applicant]
Kirstein et al., “Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered to adults 56 years of age and older”, 20th International Pathogenic Neisseria Conf… [cited by applicant]
Kirstein et al., “Safety and Immunogenicity of an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered to Adults 56 Years of Age and Older”, 20th International Pathogenic Neisseria Conf… [cited by applicant]
Klein et al., “Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children”, The Pediatric Infectious Disease Journal, 35(6)… [cited by applicant]
Klein et al., “One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children”, The Pediatric Infectious Disease Journal, 32(7)… [cited by applicant]
Knuf et al., “A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year o… [cited by applicant]
Knuf et al., “An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-mon… [cited by applicant]
Konadu et al., Preparation, characterization, and immunological properties in mice of [cited by applicant]
Lees et al., “Versatile and efficient synthesis of protein-polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry”, Vaccine, vol. 24, Issue 6, Feb. 6, 2006, pp. 716-729. [cited by applicant]
Leonardi et al., “Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™”, Vaccine 33, pp. 924-932 (2015). [cited by applicant]
Leonardi et al., “Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine(HibMenCY-TT) is immunogenic in toddlers who previously received three d… [cited by applicant]
Lupisan et al.: “Meningococcal Polysaccharide A O-Acetylation levels Do not Impact the Immunogenicity of the Quadrivalent Meningococcal Tenatus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III S… [cited by applicant]
Mcvernon et al., “A Randomized Trial to Assess Safety and Immunogenicity of Alternative Formulations of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine in Toddlers”, The Pediatric Inf… [cited by applicant]
Memish et al., “Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine Wi… [cited by applicant]
Miller et al., “Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience”, Advances in Preventive Medicine, 2011, Article ID 846756, 17 pages. [cited by applicant]
Ostergaard et al., “Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 year”, Vaccine, 27, pp… [cited by applicant]
Ostergaard et al., “Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT)”, Int J Infect Dis, 17, p… [cited by applicant]
Papaevangeloo V. et al: “MenACWY-TT vaccine for active immunization against invasive meningogoccal disease” ; Expert Review of Vaccines ; vol. 11, No. 5, 2012, pp. 523-537. [cited by applicant]
Paul et al., “N, N'-Carbonyldiimidazole, a new peptide forming reagent”, J. Am. Chem. Soc.. 82, pp. 4596-4600 (1960). [cited by applicant]
Pichichero, Michael E., “Protein carriers of conjugate vaccines”, Hum Vaccin Immunother, 9(12), pp. 2505-2523 (Dec. 1, 2013). [cited by applicant]
Reyes et al., “The investigational meningococcal serogroups A,C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in… [cited by applicant]
Sanderson et al., “A simple method for coupling proteins to insoluble polysaccharides”, Immunology, 20, pp. 1061-1065 (1971). [cited by applicant]
Tontini, Marta, “Characterization of carbohydrate based vaccines”, Phd Thesis, the University of Cergy-Pontoise, Oct. 26, 2012. [cited by applicant]
Van Lenten et al., “Studies on the chemical and enzymatic modifications of glycoproteins. A general method for the tritiation of sialic acid-containing glycoproteins.”, J. Biol. Chem, 246:1889-1894 (1971). [cited by applicant]
Vesikari et al., “A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years… [cited by applicant]
Vesikari et al., “Antibody persistence to meningococcal serogroups A, C, W and Y in toddlers two years after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate (MenACWY-TT) vaccine as measured b… [cited by applicant]
Vesikari et al., “Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococoal ACWY-tetanus toxoid conjugate vaccine”, Human Vacci… [cited by applicant]
Vesikari et al., “Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administ… [cited by applicant]
Wilchek et al., “Labeling glycoconjugates with hydrazide reagents”, Methods in Enzymology (V. Ginsburg, ed.), vol. 138, p. 429-442 (1987). [cited by applicant]
Yang et al., “New Advances in meningococcal vaccine research”, China Tropical Medicine, 10, pp. 2064-2066 (2009). [cited by applicant]
Knuf et al., “Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate… [cited by applicant]
Kensinger et al., “Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi®,” Glycoconjugate Journal, 39:381-392 (2022), with supplemental data (9 pages). [cited by applicant]